: Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

<p>Organon &#38; Co. OGN and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie’ Inc.’s ABBV rheumatoid arthritis drug that is one of the best selling biopharma products of all time, was opened to biosimilar competition on July 1 after losing its [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/market-news/organon-and-samsung-bioepis-launch-humira-biosimilar-hadlima-in-the-u-s/">: Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>